Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04680884
Other study ID # APHP180584
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date December 21, 2020
Est. completion date December 21, 2023

Study information

Verified date December 2020
Source Assistance Publique - Hôpitaux de Paris
Contact Elie Azoulay, Pr
Phone +331 42 49 34 21
Email elie.azoulay@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute respiratory failure (ARF) is the leading reason of ICU admission in immunocompromised patients. Failure to identify the ARF etiology is associated with increased mechanical ventilation and mortality rates. This was confirmed in the large Efraim 1 study published in 2017, where undetermined ARF etiology affected 609/1611 (38%) patients at day 3, 402 (25%) patients at day 7 and 199 (12.3%) patients overall, and was associated with a case fatality of 55% (vs. 40% in other patients). In lung biopsy/autopsy findings from these patients, invasive fungal infection, steroid-sensitive affections (organized pneumonia, non-infectious interstitial involvement, drug-related pulmonary toxicity…), and lung infiltration by the underlying disease (lymphoma, carcinomatous lymphangitis, systemic vasculitis, connective tissue diseases, etc.) were the leading etiologies. No study has evaluated survival benefits from empirical steroids and/or antifungals in immunocompromised patients with ARF from undetermined etiology. The main objective of this study is to reduce the 90-day mortality in immunocompromised patients with ARF from undetermined etiology at day-3. The intervention would evaluate the impact of steroids ± isavuconazole for 14 days or until ICU discharge.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 420
Est. completion date December 21, 2023
Est. primary completion date September 21, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Age >18 years and < 90 years - Known immunosuppression: 1. immunosuppressive drug 2. solid organ transplant 3. solid tumor 4. hematological malignancies 5. primary immune deficiency - ICU admission for acute respiratory failure as defined by 1. respiratory distress with tachypnea (respiratory rate>30/min) 2. cyanosis 3. laboured breathing 4. need for more than 6L of standard oxygen to maintain SpO2>95%, or for high flow oxygen, non-invasive or invasive mechanical ventilation - No established ARF etiology at day 3 - Informed consent signed: - by the patient, - Or informed consent signed by a family members/trustworthy person if his condition does not allow him to express his consent in written as per L1111-6, - Or in an emergency situation and in the absence of family members/trustworthy person, the patient can be enrolled. The consent to participate to the research will be requested as soon as the condition of the patient will allow). Note: Patient with Pneumocystis pneumonia can be included given that their treatment does not require the use of neither antifungal drugs nor corticosteroids Exclusion Criteria: - Patient who improved enough to be discharged from the ICU at day 3 - Documented invasive fungal infection that requires antifungal therapy. - Patient needing or receiving prophylactic or empirical antifungal treatment for clinical care - Patient needing or receiving corticoid therapy - Patient receiving palliative care with comfort measures only (Do Not Intubate (DNI) and Do Not Resuscitate (DNR) patients can be included) - Pregnant or breastfeeding patient - No social security coverage - Known hypersensitivity to isavuconazole or to any of excipients of CRESEMBA® specialty - Patient treated by ketoconazole, ritonavir, or any CYP3A4/5 inductor - Short QT syndrome and/or patient with a family history of short QT syndrome; - Liver insufficiency (any stage) - Moribund patients - Participation in another interventional research

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Experimental for steroid
2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
Experimental for antifungals
IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
Experimental for steroids and antifungals
IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
Other:
Standard of care
IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality Overall death at day 90
Secondary ICU mortality Mortality at ICU discharge at ICU discharge within 6 months
Secondary Hospital mortality Mortality at hospital discharge at hospital discharge within 6 months
Secondary Mortality Overall death at day 28
Secondary Proportion of patients with ICU acquired microbiologically documented bacterial infections at day 28
Secondary Proportion of patients with invasive fungal infection at day 28
Secondary Proportion of patients with herpes simplex virus (HSV) reactivation at day 28
Secondary Proportion of patients with varicella-zoster virus (VZV) reactivation at day 28
Secondary Proportion of patients with cytomegalovirus (CMV) reactivation at day 28
Secondary Occurrence of severe hypokalemia Severe hypokalemia will be defined as kalemia <2,5 meq/l at day 28
Secondary Occurence of decompensated diabetes at day 28
Secondary Occurence of severe or newly acquired hypertension at day 28
Secondary Emergence of aspergillus species at day 28
Secondary Incidence of candida infection at day 28
Secondary Incidence of post-traumatic Stress Disorder Post-traumatic Stress Disorder will be evaluated using IES-R scale. Impact of Event Scale - Revised (IES-R) is a 22-item self-report measure that assesses subjective distress caused by traumatic events. The higher the score, the more severe the symptoms. at 6 months
Secondary Incidence of anxiety and depression Depression and anxiety will be assessed using Hospital Anxiety and Depression Scale (HADS) questionnaire. HADS is a self-administered scale of 14 items which assessed levels of depression and anxiety, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales (sum of the 7 items, ranging from 0 to 21). Limit scores : clearly or clinically symptomatic cases (score = 11). at 6 months
Secondary Quality of life Quality of life will be evaluated using SF36. SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting. Items are grouped into three categories: functional status, well-being, overall health assessment. In two dimensions, the answer is binary (yes / no) and in the other 6 in ordinal quality (3 to 6 possible answers). For each dimension, the scores for the different items are coded and then summed and transformed linearly on a scale ranging from 0 to 100. A physical composite score and a mental composite score can be calculated according to an established algorithm at 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05144633 - Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Recruiting NCT03021902 - Nutrition and Exercise in Critical Illness Phase 2
Completed NCT02902146 - Bougie Use in Emergency Airway Management N/A
Completed NCT02901158 - Esophageal Manometry in Mechanically Ventilated Patients
Completed NCT02236559 - High Flow Therapy for the Treatment of Respiratory Failure in the ED N/A
Recruiting NCT02056093 - Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Terminated NCT01083277 - Variable Ventilation During Acute Respiratory Failure N/A
Completed NCT01462279 - Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness N/A
Completed NCT01114022 - Prevention Inhalation of Bacterial by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane N/A
Active, not recruiting NCT01058421 - Treatment of Critical Illness Polyneuromyopathy Phase 2
Completed NCT00252616 - Timing of Target Enteral Feeding in the Mechanically Ventilated Patient Phase 2/Phase 3
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting NCT06051292 - Decremental Esophageal Catheter Filling Volume Titration For Transpulmonary Pressure Measurement N/A
Completed NCT04601090 - Survival Rates and Longterm Outcomes After COVID-19
Recruiting NCT05423301 - Global Physiotherapy in ICU Patients With High Risk Extubation Failure N/A
Completed NCT02447692 - Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study N/A
Completed NCT04016480 - HFNC During Bronchoscopy for Bronchoalveolar Lavage N/A
Completed NCT04507425 - High Flow Nasal Cannula With Noninvasive Ventilation N/A